查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1231547

女性健康治疗的全球市场

Women's Health Therapeutics
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 92 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

女性健康治疗的全球市场2030年前将达到454亿美元

在COVID-19后改变的商务环境中，2022年134亿美元的市场规模·估计价值，2030年前将达到454亿美元，预计在2022年～2030年预计将以年复合成长率16.5％增长。本报告所分析之市场区隔之一的停经后骨质疏鬆症将记录年复合成长率19.5％，到分析期间结束时将达到181亿美元。考虑疫情后的復苏，荷尔蒙性不孕症领域今后8年的年复合成长率将修正为13.3％。

美国市场估算为37亿美元，中国则将以年复合成长率22.4％增长

美国的女性健康治疗市场在2022年估算为37亿美元。作为世界第2大经济大国的中国，在2022年～2030年复合成长率预计将为22.4％，2030年达到113亿美元的市场规模。其他热门的地区市场有日本和加拿大，在2022年～2030年预计将各以10.7％和14.3％的速度成长。在欧洲市场中，德国预计将以年复合成长率12.6％成长。

调查对像企业范例

  • AstraZeneca
  • Bayer AG
  • Bristol-Myers Squibb Company
  • CooperSurgical, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG

目录

第1章 调查手法

第2章 摘要整理

  • 市场概要
  • 主要企业
  • 市场趋势与推动因素
  • 全球市场预测

第3章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美国家
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯联合大公国
  • 其他中东
  • 非洲

第4章 竞争

简介目录
Product Code: MCP23094

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Women's Health Therapeutics Market to Reach $45.4 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Women's Health Therapeutics estimated at US$13.4 Billion in the year 2022, is projected to reach a revised size of US$45.4 Billion by 2030, growing at aCAGR of 16.5% over the period 2022-2030. Postmenopausal Osteoporosis, one of the segments analyzed in the report, is projected to record 19.5% CAGR and reach US$18.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Hormonal Infertility segment is readjusted to a revised 13.3% CAGR for the next 8-year period.

The U.S. Market is Estimated at $3.7 Billion, While China is Forecast to Grow at 22.4% CAGR

The Women's Health Therapeutics market in the U.S. is estimated at US$3.7 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$11.3 Billion by the year 2030 trailing a CAGR of 22.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.7% and 14.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 12.6% CAGR.

Select Competitors (Total 36 Featured):

  • AstraZeneca
  • Bayer AG
  • Bristol-Myers Squibb Company
  • CooperSurgical, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Women's Health Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Women's Health Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Women's Health Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Women's Health Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Postmenopausal Osteoporosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Postmenopausal Osteoporosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Hormonal Infertility by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Hormonal Infertility by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Hormonal Infertility by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Polycystic Ovary Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Polycystic Ovary Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for Polycystic Ovary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Endometriosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Endometriosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 15: World 16-Year Perspective for Endometriosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Contraceptives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Contraceptives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 18: World 16-Year Perspective for Contraceptives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Menopause by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Menopause by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 21: World 16-Year Perspective for Menopause by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 24: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 25: World Women's Health Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Women's Health Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • JAPAN
    • Women's Health Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • CHINA
    • Women's Health Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 37: China 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • EUROPE
    • Women's Health Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Women's Health Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for Women's Health Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 40: Europe 16-Year Perspective for Women's Health Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • FRANCE
    • Women's Health Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 44: France Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: France Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 46: France 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • GERMANY
    • Women's Health Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 47: Germany Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Germany Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 49: Germany 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 50: Italy Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Italy Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 52: Italy 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Women's Health Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 53: UK Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 54: UK Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 55: UK 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • SPAIN
    • TABLE 56: Spain Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Spain Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 58: Spain 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • RUSSIA
    • TABLE 59: Russia Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Russia Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 61: Russia 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 62: Rest of Europe Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Rest of Europe Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 64: Rest of Europe 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Women's Health Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 65: Asia-Pacific Recent Past, Current & Future Analysis for Women's Health Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 66: Asia-Pacific Historic Review for Women's Health Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 67: Asia-Pacific 16-Year Perspective for Women's Health Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
    • TABLE 68: Asia-Pacific Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Asia-Pacific Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 70: Asia-Pacific 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • AUSTRALIA
    • Women's Health Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 71: Australia Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 72: Australia Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 73: Australia 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • INDIA
    • Women's Health Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 74: India Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: India Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 76: India 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • SOUTH KOREA
    • TABLE 77: South Korea Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: South Korea Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 79: South Korea 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 80: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Rest of Asia-Pacific Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 82: Rest of Asia-Pacific 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • LATIN AMERICA
    • Women's Health Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 83: Latin America Recent Past, Current & Future Analysis for Women's Health Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 84: Latin America Historic Review for Women's Health Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 85: Latin America 16-Year Perspective for Women's Health Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2023 & 2030
    • TABLE 86: Latin America Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Latin America Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 88: Latin America 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • ARGENTINA
    • TABLE 89: Argentina Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Argentina Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 91: Argentina 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • BRAZIL
    • TABLE 92: Brazil Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Brazil Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 94: Brazil 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • MEXICO
    • TABLE 95: Mexico Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Mexico Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 97: Mexico 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 98: Rest of Latin America Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Rest of Latin America Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 100: Rest of Latin America 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • MIDDLE EAST
    • Women's Health Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 101: Middle East Recent Past, Current & Future Analysis for Women's Health Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 102: Middle East Historic Review for Women's Health Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 103: Middle East 16-Year Perspective for Women's Health Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2023 & 2030
    • TABLE 104: Middle East Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Middle East Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 106: Middle East 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • IRAN
    • TABLE 107: Iran Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Iran Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 109: Iran 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • ISRAEL
    • TABLE 110: Israel Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Israel Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 112: Israel 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • SAUDI ARABIA
    • TABLE 113: Saudi Arabia Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 114: Saudi Arabia Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 115: Saudi Arabia 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 116: UAE Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 117: UAE Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 118: UAE 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 119: Rest of Middle East Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 120: Rest of Middle East Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 121: Rest of Middle East 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030
  • AFRICA
    • Women's Health Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • TABLE 122: Africa Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 123: Africa Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 124: Africa 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2023 & 2030

IV. COMPETITION